Journal for ImmunoTherapy of Cancer (Nov 2021)

481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors

  • Rui Wang,
  • Judy Wang,
  • Siqing Fu,
  • Arun Azad,
  • Gerald Falchook,
  • Minal Barve,
  • Hui Gan,
  • Tarek Meniawy,
  • Meredith McKean,
  • Tira Tan,
  • Giovanni Abbadessa,
  • David Sommerhalder,
  • Chen Chee,
  • charlotte Lemeque,
  • Nicole Acuff,
  • Helene Pham,
  • Jill Mooney,
  • Neyssa Marina

DOI
https://doi.org/10.1136/jitc-2021-SITC2021.481
Journal volume & issue
Vol. 9, no. Suppl 2

Abstract

Read online

No abstracts available.